Lipocine (LPCN)
(Delayed Data from NSDQ)
$7.85 USD
-0.30 (-3.68%)
Updated Jun 26, 2024 03:58 PM ET
After-Market: $7.79 -0.06 (-0.76%) 7:08 PM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
Brokerage Reports
Lipocine Inc. [LPCN]
Reports for Purchase
Showing records 81 - 100 ( 106 total )
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
CRL Issued on LPCN 1021 Over Its Dose-Adjustment Protocol
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Q1 Lower on Launch Prep, TLANDO (LPCN 1021) PDUFA June 28
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
1107?s Progesterone Plasma > Makena; PT Up $4 to $40
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Enrollment of LPCN 1111, Potentially First Once-a-day TRT, Is Underway
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Lack of AdCom Reduces LPCN 1021?s Regulatory Risk, as BD Season Begins
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
2Q15 Generally Inline; As Lipocine Starts To Bulk Up.
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Lipocine Inc.
Industry: Medical - Drugs
LPCN Initiation: LPCN 1021, On Track To Become First Oral TRT in $2.5B Market
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M